$BBOT News

Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook

Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers

BBOT to Participate in Upcoming Investor Healthcare Conferences

JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?